Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
Marscha S. Holleman, Maiwenn J. Al, Remziye Zaim, Harry J. M. Groen, Carin A. Uyl-de Groot
| Year of publication: |
2020
|
|---|---|
| Authors: | Holleman, Marscha S. ; Al, Maiwenn J. ; Zaim, Remziye ; Groen, Harry J. M. ; Uyl-de Groot, Carin A. |
| Published in: |
The European journal of health economics : HEPAC ; health economics in prevention and care. - Berlin : Springer, ISSN 1618-7598, ZDB-ID 2045253-6. - Vol. 21.2020, 1, p. 153-164
|
| Subject: | Cost-effectiveness analysis | Non-small cell lung cancer | EGFR-TKI | Gefitinib | Erlotinib | Afatinib | Osimertinib | Kosten-Wirksamkeits-Analyse | Krebskrankheit | Cancer | Theorie | Theory | Patienten | Patients |
| Type of publication: | Article |
|---|---|
| Type of publication (narrower categories): | Aufsatz in Zeitschrift ; Article in journal |
| Language: | English |
| Other identifiers: | 10.1007/s10198-019-01117-3 [DOI] |
| Source: | ECONIS - Online Catalogue of the ZBW |
Persistent link: https://www.econbiz.de/10012221645